Claims for Patent: 5,869,254
✉ Email this page to a colleague
Summary for Patent: 5,869,254
Title: | Alteration of sequence of a target molecule by ribozyme catalyzed trans-splicing |
Abstract: | Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule. |
Inventor(s): | Sullenger; Bruce A. (Westminster, CO), Cech; Thomas R. (Boulder, CO) |
Assignee: | University Research Corporation (Boulder, CO) |
Application Number: | 08/786,753 |
Patent Claims: | 1. A method for splicing a non-viral target nucleic acid molecule with a separate nucleic molecule, wherein said target nucleic acid molecule includes a nucleic acid sequence
deleterious to an organism in which it is located, and wherein said separate nucleic acid molecule is adapted to correct said defect after splicing with said target molecule, comprising the step of:
contacting said target nucleic acid molecule in a cell in vitro with said separate nucleic acid molecule in the presence of one or more spliceosomes or splicing factors under conditions in which at least a portion of said separate nucleic acid molecule is spliced with at least a portion of said target nucleic acid molecule to form a non-deleterious nucleic acid molecule. 2. A method for splicing a non-viral target nucleic acid molecule with a separate nucleic molecule comprising a catalytic nucleic acid molecule, wherein said target nucleic acid molecule includes a nucleic acid sequence deleterious to an organism in which it is located, and wherein said separate nucleic acid molecule is adapted to correct said defect after splicing with said target molecule, comprising the step of: contacting said target nucleic acid molecule in a cell in vitro with said separate nucleic acid molecule comprising a catalytic nucleic acid molecule in the presence of one or more spliceosomes or splicing factors under conditions in which at least a portion of said separate nucleic acid molecule is spliced with at least a portion of said target nucleic acid molecule to form a non-deleterious nucleic acid molecule. 3. The method of claim 2, wherein said catalytic nucleic acid molecule is active to cleave said target nucleic acid molecule and to splice said separate nucleic acid molecule with said target nucleic acid molecule. 4. The method of claims 2 or 3, wherein said catalytic nucleic acid molecule is a group I or group II intron molecule. 5. The method of claims 1 or 3, wherein said target nucleic acid molecule is an RNA molecule. 6. The method of claims 1 or 3, wherein said contacting comprises providing an expression vector encoding said separate nucleic acid molecule. |
Details for Patent 5,869,254
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2013-11-12 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2013-11-12 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2013-11-12 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.